Form 8-K · Current report
Abbott Laboratories 8-K, filed Oct 21, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001104659-26-117587
Summary
Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free share distribution to Abbott shareholders, expected to be completed by the end of 2027 subject to regulatory approvals and board approval. CEO Robert B. Ford said the separation would let both companies pursue distinct growth strategies, and Daniel Salvadori, currently executive vice president and group president of Established Pharmaceuticals and Nutritional Products, will become CEO of the new Nutrition company.
Key points
- The new Nutrition company would have approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites, with brands including Similac, PediaSure, Pedialyte, Glucerna and Ensure.
- Abbott would retain approximately $42 billion in sales, with businesses in medical devices, diagnostics, biowearables and established medicines.
- Abbott expects the combined dividend paid by Abbott and the new Nutrition company to equal Abbott's dividend at the time of separation.
- Goldman Sachs & Co. LLC is financial advisor and Wachtell, Lipton, Rosen & Katz is legal counsel to Abbott on the transaction.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. Filed as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing that it plans to separate its global nutrition business into an independent, publicly traded company. Item 9.01 Financial Statements and Exhibits. Exhibit No. Exhibit 99.1 Press Release dated October 21, 2026. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) Exhibit 99.1: EX-99.1 2 tm2627971d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.